Literature DB >> 32275802

Intraoperative Continuous Renal Replacement Therapy During Liver Transplantation: A Meta-Analysis.

Hui-Bin Huang1, Yuan Xu1, Hua Zhou1, Yan Zhu1, Jun-Ping Qin1.   

Abstract

Continuous renal replacement therapy (CRRT) is frequently used to treat recipients with renal failure before or after liver transplantation (LT), though evidence supporting its use during surgery remains unclear. Therefore, we conducted a quantitative meta-analysis to evaluate the effect of intraoperative continuous renal replacement therapy (IORRT) in recipients with pretransplant severe renal dysfunction. We searched PubMed, Embase, and the Cochrane database for trials focusing on LT recipients supported with or without IORRT. Outcomes assessed were mortality, preoperative characteristics, intraoperative data, and predefined postoperative outcomes. Seven trials with 1051 recipients were eligible. Preoperatively, the IORRT group recipients had higher Model for End-Stage Liver Disease scores (weighted mean difference [WMD], 6.19; 95% confidence interval [CI], 2.51-9.87), Charlson scores (WMD, 0.45; 95% CI, 0.09-0.80), acute liver failure (odds ratio [OR], 1.82; 95% CI, 1.27-2.61), serum creatinine (WMD, 71.33 μmol/L; 95% CI, 1.98-140.69 μmol/L), total bilirubin level (WMD, 5.05 μmol/L; 95% CI, 1.75-8.35 μmol/L), intensive care unit admission (OR, 3.53; 95% CI, 1.23-10.13), vasoactive therapy (OR, 3.80; 95% CI, 2.64-5.46), ventilator care (OR, 2.52; 95% CI, 1.18-5.35), and renal replacement therapy (RRT) (OR, 29.37; 95% CI, 7.66-112.54) compared with control patients. IORRT patients also required more intraoperative blood product transfusion and had more post-LT RRT (OR, 25.67; 95% CI, 4.92-133.85). However, there were no significant differences in short-term mortality (OR, 2.12; 95% CI, 0.82-5.44) between the groups. In addition, worse longterm mortality was seen in the IORRT group. In conclusion, IORRT is feasible and safe and may help sicker recipients tolerate the LT procedure to achieve short-term clinical outcomes comparable with less ill patients without IORRT. More high-quality evidence is needed to verify our conclusion in the future.
Copyright © 2020 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2020        PMID: 32275802     DOI: 10.1002/lt.25773

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  2 in total

Review 1.  Management of acute renal replacement therapy in critically ill cirrhotic patients.

Authors:  Jimena Del Risco-Zevallos; Alicia Molina Andújar; Gastón Piñeiro; Enric Reverter; Néstor David Toapanta; Miquel Sanz; Miquel Blasco; Javier Fernández; Esteban Poch
Journal:  Clin Kidney J       Date:  2022-01-28

2.  Continuous renal replacement therapy and transplant-free survival in acute liver failure: protocol for a systematic review and meta-analysis.

Authors:  Andrea M Robinson; C J Karvellas; Joanna C Dionne; Robin Featherstone; Meghan Sebastianski; Ben Vandermeer; Oleksa G Rewa
Journal:  Syst Rev       Date:  2020-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.